ONWARD Medical: ONWARD to Attend Upcoming Scientific and Investor Events

EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA, April 12, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announced that management will attend the following conferences in the upcoming weeks:

• ASIA 50th Annual Scientific Meeting (https://asia-spinalinjury.org/2023-annual-scientific-meeting/) (American Spinal Injury Association)
  April 17-19, 2023
  Atlanta, GA, US
  Dave Marver, CEO, will attend and participate in the conference.

• Needham Annual Healthcare Conference
  April 17-20, 2023
  Virtual Event
  Lara Smith Weber, CFO, will give a company presentation.

• DMGP Congress (https://dmgp-kongress.de/) (36th Annual Meeting of the German-Speaking Medical Society for Paraplegia)
  April 19-22
  Nottwil, Switzerland
  Grégoire Courtine, CSO, will deliver the keynote address with Dr. Jocelyne Bloch.

• LSX World Congress
  (https://www.lsxleaders.com/lsx-world-congress)May 3-4, 2023
  London, UK
  Dave Marver, CEO, will attend and serve on a panel.

• "Invest & Connect" by KPMG & the Vaud Chamber of Commerce and Industry (CVCI)
  June 13, 2023
  Lausanne, Switzerland
  Lara Smith Weber, CFO, will deliver the keynote address at this start-up event.

• Stifel European Healthcare Conference
  June 28-30, 2023
  Bordeaux, France
  Dave Marver, CEO, will attend and participate in the conference.

Information on upcoming conferences and events is available in the investor section of the ONWARD website at https://ir.onwd.com/news-events.

About ONWARD Medical

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury and other movement disabilities.

ONWARD has received eight Breakthrough Device Designations from the US FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a stimulator and wireless programmer. Positive top-line data were reported in 2022 from the Company's first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The Company is now preparing marketing approval submissions for the US and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The Company completed first-in-human use of the ARC-IM neurostimulator and reported positive interim clinical outcomes for ARC-IM Therapy for improved blood pressure regulation following SCI in 2022.

ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The Company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology. To access our 2023 Financial Calendar, please visit IR.ONWD.com.

For Company Enquiries:

[e-mail]

For Media Enquiries:

MC Services AG
US: Laurie Doyle, P: [phone]
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka, P: [phone]
[e-mail]

For Investor Enquiries:

[e-mail]

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.